Why Melanoma Is Deadlier in Darker Skin Even Though It Is Rarer

Melanoma is far less common in darker skin, yet it takes a larger share of the people it reaches. The reason is not that pigment makes the tumor more aggressive by nature; it is that these cancers are usually caught later, tend to appear in places routine sun-protection advice ignores, and are more often a biologically distinct, largely UV-independent subtype. In the United States, 5-year relative survival for melanoma sits near 66% among non-Hispanic Black patients compared with roughly 90% among non-Hispanic White patients, and most of that gap traces back to stage at diagnosis rather than skin color itself.

A rarer cancer with a heavier toll

The numbers look contradictory until you separate incidence from outcome. Data compiled in Preventing Chronic Disease put melanoma incidence among non-Hispanic Black Americans near 1.0 per 100,000, a small fraction of the rate in non-Hispanic White Americans. Despite that lower incidence, the same analysis reported a 5-year relative survival of 66.2% for non-Hispanic Black patients versus 90.1% for non-Hispanic White patients. The 2023 review "Melanoma in skin of color" in the Journal of the American Academy of Dermatology frames the pattern plainly: incidence is higher in White individuals, but melanoma-specific survival is worse in people with skin of color.

Found late, not born worse

Stage at diagnosis explains most of the survival gap. In the Preventing Chronic Disease data, only about half of melanomas in non-Hispanic Black patients were localized when found, compared with roughly three-quarters in White patients, meaning a far larger share had already reached regional nodes or distant sites. A tumor caught while thin and confined is usually curable with surgery, while the same tumor found after it invades deeper carries a very different prognosis. So the question worth asking is why these cancers surface later.

The JAAD review points to several overlapping reasons, none of them about biology alone: less skin-cancer education directed at people with skin of color, lower rates of screening, socioeconomic and access barriers, a higher proportion of aggressive subtypes, and underrepresentation of darker skin in research and professional training. Each adds delay, and in melanoma delay is measured in millimeters of tumor depth.

Where these melanomas hide

Part of the problem is location. The most common clearly defined subtype in Black patients is acral lentiginous melanoma, which arises on the palms, the soles of the feet, and under the nails. In the Preventing Chronic Disease series it accounted for the largest share of cases with a specified histology. These are not the sun-exposed spots people are taught to watch, and they are easy to shrug off as a bruise, a callus, or a nail injury. The most-cited illustration is the musician Bob Marley, who died in 1981 of an acral melanoma that began under a toenail and was first mistaken for a soccer injury.

This is also where the UV story diverges. High, intermittent sun exposure in childhood is a well-established, modifiable risk factor for melanoma in lighter skin. For darker skin, the JAAD review notes that data linking UV to melanoma risk are limited, and acral and subungual tumors sit on skin the sun barely reaches. Prevention messaging built entirely around sunscreen and sunburn, useful as it is, simply does not map onto a cancer that can appear on the bottom of a foot.

The training gap behind the delay

Dermatology is a pattern-recognition specialty, and clinicians learn those patterns from images. When darker skin is scarce in textbooks, atlases, and journals, that gap follows trainees into the exam room. The JAAD review highlights this underrepresentation in professional education as one driver of missed and delayed diagnoses, and analyses of teaching materials have repeatedly found that images of dark skin make up only a small minority of what students see.

The diagnostic shorthand carries the same bias. The familiar ABCDE checklist (asymmetry, border, color, diameter, evolving) was shaped largely around melanomas as they present on lighter skin. Acral and nail lesions often need different cues, such as a new or widening pigmented band on a single nail, pigment spilling onto the surrounding skin fold, or a sore on the sole that will not heal.

What moves the needle

The disparity is largely a detection problem, which means it is partly fixable. Skin checks that include the palms, soles, spaces between the toes, and the nails catch tumors that sun-focused exams miss. Broadening the images used to train clinicians, and lowering the barriers that push a first visit later, target the delay directly. This article is educational and not a substitute for personal medical advice, but a persistent, changing, or bleeding spot in any of those overlooked places is worth showing to a qualified professional promptly rather than watching it.

The deeper lesson generalizes past dermatology. When the evidence base, the teaching images, and the screening scripts are all built around one group, the people outside that frame pay for it in stage at diagnosis and survival, even for a disease they are statistically less likely to get.